Popular Trials
Janus Kinase (JAK) Inhibitor
Ruxolitinib Cream for Hand Eczema
This trial is testing a cream called ruxolitinib for adults with chronic hand eczema that is moderate to severe. The cream works by blocking enzymes that cause inflammation, which may help reduce eczema symptoms. The goal is to see if this treatment is safe and effective for these patients.
Monoclonal Antibodies
Nemolizumab for Eczema
This trial is testing nemolizumab, a medication designed to help children with moderate-to-severe eczema. Nemolizumab is a medication developed for treating skin diseases, including severe eczema. The drug works by blocking proteins that cause skin problems and itching. Researchers aim to see how well it works and if it is safe for these children.
Behavioural Intervention
Preventative Skin Care for Pediatric Brain Cancer
This trial tests a skin care routine for children with brain tumors undergoing cancer treatments. The routine includes gentle skin care, sun protection, and bleach baths. It aims to reduce skin problems caused by the treatments.
Monoclonal Antibodies
Lebrikizumab for Eczema
This trial is testing the safety and effectiveness of lebrikizumab, a medication for eczema. It targets people with moderate-to-severe atopic dermatitis, including those from previous studies and new participants. Lebrikizumab works by blocking a protein that causes inflammation and itching.
Popular Filters
Trials for Atopic Dermatitis Patients
Barrier Cream
Skin Barrier Cream + Fluticasone Propionate for Eczema
This trial is testing whether using a special moisturizing cream and a mild steroid cream can help infants with early signs of eczema. The goal is to see if this treatment can reduce eczema severity and prevent food allergies. The study focuses on very young babies who have dry skin or early eczema symptoms. EpiCeramâ„¢ has been previously tested for preventing eczema in infants with a family history of allergic disease.
Janus Kinase (JAK) Inhibitor
Upadacitinib for Eczema
This trial is testing upadacitinib, an oral medication, to see if it can help people with severe eczema. The medication works by calming down the overactive immune system to reduce skin inflammation and itching. Upadacitinib is approved in many countries for the treatment of atopic dermatitis in individuals whose disease is not adequately controlled with other treatments or when those treatments are not suitable.
Janus Kinase (JAK) Inhibitor
Abrocitinib for Atopic Dermatitis/Eczema
This trial is testing a pill called Abrocitinib to help people aged 12 and older with severe eczema. It aims to see if the pill can reduce inflammation and itching by blocking certain body chemicals. The study includes patients who have already participated in a related study.
Trials for AD Patients
Barrier Cream
Skin Barrier Cream + Fluticasone Propionate for Eczema
This trial is testing whether using a special moisturizing cream and a mild steroid cream can help infants with early signs of eczema. The goal is to see if this treatment can reduce eczema severity and prevent food allergies. The study focuses on very young babies who have dry skin or early eczema symptoms. EpiCeramâ„¢ has been previously tested for preventing eczema in infants with a family history of allergic disease.
Janus Kinase (JAK) Inhibitor
Upadacitinib for Eczema
This trial is testing upadacitinib, an oral medication, to see if it can help people with severe eczema. The medication works by calming down the overactive immune system to reduce skin inflammation and itching. Upadacitinib is approved in many countries for the treatment of atopic dermatitis in individuals whose disease is not adequately controlled with other treatments or when those treatments are not suitable.
Janus Kinase (JAK) Inhibitor
Abrocitinib for Atopic Dermatitis/Eczema
This trial is testing a pill called Abrocitinib to help people aged 12 and older with severe eczema. It aims to see if the pill can reduce inflammation and itching by blocking certain body chemicals. The study includes patients who have already participated in a related study.
Phase 3 Trials
Janus Kinase (JAK) Inhibitor
Upadacitinib for Eczema
This trial is testing upadacitinib, an oral medication, to see if it can help people with severe eczema. The medication works by calming down the overactive immune system to reduce skin inflammation and itching. Upadacitinib is approved in many countries for the treatment of atopic dermatitis in individuals whose disease is not adequately controlled with other treatments or when those treatments are not suitable.
Janus Kinase (JAK) Inhibitor
Abrocitinib for Atopic Dermatitis/Eczema
This trial is testing a pill called Abrocitinib to help people aged 12 and older with severe eczema. It aims to see if the pill can reduce inflammation and itching by blocking certain body chemicals. The study includes patients who have already participated in a related study.
Monoclonal Antibodies
Dupilumab for Eczema
This trial is testing the long-term safety and efficacy of dupilumab, a medication used to treat eczema, in children. The trial will also assess the levels of functional dupilumab in the blood after repeated treatment and the immunogenicity of the medication.
Trials With No Placebo
Barrier Cream
Skin Barrier Cream + Fluticasone Propionate for Eczema
This trial is testing whether using a special moisturizing cream and a mild steroid cream can help infants with early signs of eczema. The goal is to see if this treatment can reduce eczema severity and prevent food allergies. The study focuses on very young babies who have dry skin or early eczema symptoms. EpiCeramâ„¢ has been previously tested for preventing eczema in infants with a family history of allergic disease.
Monoclonal Antibodies
Dupilumab for Eczema
This trial is testing the long-term safety and efficacy of dupilumab, a medication used to treat eczema, in children. The trial will also assess the levels of functional dupilumab in the blood after repeated treatment and the immunogenicity of the medication.
View More Related Trials
Frequently Asked Questions
Introduction to seborrheic dermatitis
What are the top hospitals conducting seborrheic dermatitis research?
When it comes to finding innovative solutions for seborrheic dermatitis, several hospitals are leading the way in clinical research. In sunny Los Angeles, Dermatology Research Associates is at the forefront with an impressive 14 ongoing trials focused on this common skin condition. This dedicated institution is committed to investigating new treatments and improving the lives of those affected by seborrheic dermatitis. Meanwhile, First OC Dermatology in Fountain Valley has also positioned itself as a top contender, conducting ten active trials aimed at combating this bothersome condition that affects millions worldwide.
Down in San Antonio, Progressive Clinical Research is making significant strides with eight current seborrheic dermatitis trials. This Texas-based institute recognizes the importance of finding effective therapies for this chronic inflammatory disorder that commonly affects areas such as the scalp and face. Additionally contributing to the advancement of treatment options is Dawes Fretzin Clinical Research Group LLC in Indianapolis, where seven active studies are underway specifically targeting seborrheic dermatitis.
And let's not forget about Santa Monica's Clinical Science Institute, where groundbreaking research into seborrheic dermatitis is being conducted through seven ongoing clinical trials. With their collective efforts and dedication to understanding this frustrating skin condition better, these hospitals are offering hope to individuals who have long struggled with its symptoms.
Seborrheic dermatitis may seem like a minor inconvenience compared to other medical conditions; however, it can significantly impact one's quality of life due to its persistent nature and potential social implications. These pioneering institutions recognize that even seemingly benign conditions deserve attention and resources for improved management and patient comfort. Through their tireless pursuit of knowledge and innovation in treating seborrheic dermatitis, they bring us closer to effective remedies that will alleviate discomfort while restoring confidence in those affected by this often underestimated skin issue
Which are the best cities for seborrheic dermatitis clinical trials?
The best cities for seborrheic dermatitis clinical trials include Miami, Florida with 74 active studies focusing on Lebrikizumab, Nemolizumab, etrasimod, and other treatments. Los Angeles, California is another top city with 49 ongoing trials investigating Lebrikizumab, Upadacitinib, Nemolizumab, and additional interventions. Tampa in Florida follows closely behind with 48 active trials studying Nemolizumab, Lebrikizumab, AK002, and others. Each of these cities provides individuals suffering from seborrheic dermatitis access to cutting-edge clinical research that may lead to significant advancements in care.
Which are the top treatments for seborrheic dermatitis being explored in clinical trials?
Seborrheic dermatitis, a common skin condition characterized by redness and flaking, is the subject of ongoing clinical trials exploring potential treatments. Among the top contenders are:
- Ketoconazole: An antifungal medication showing promise in combating seborrheic dermatitis.
- Pimecrolimus: A nonsteroidal anti-inflammatory drug that may help alleviate symptoms associated with this condition.
- Ciclopirox olamine: An antifungal agent being investigated for its effectiveness in managing seborrheic dermatitis.
These treatments are part of a broader effort to find effective solutions for individuals suffering from seborrheic dermatitis, offering hope for improved quality of life and relief from the bothersome symptoms it presents.
What are the most recent clinical trials for seborrheic dermatitis?
Exciting advancements in the field of seborrheic dermatitis research are bringing new hope to those affected by this condition. Recent clinical trials have explored various treatment options, including a combination therapy that has shown promising results during Phase 2 testing. Additionally, Stage 1_PF-07275315 and IMG-007 Dose 1 have demonstrated potential benefits for treating seborrheic dermatitis patients, with both undergoing Phase 2 evaluation. Other studies have focused on evaluating the effectiveness of Dupilumab and Ruxolitinib in managing symptoms associated with seborrheic dermatitis. These ongoing trials hold promise in expanding our understanding of treatment possibilities and improving outcomes for individuals dealing with this challenging skin condition.
What seborrheic dermatitis clinical trials were recently completed?
A recent completion of a clinical trial brings hope for those affected by seborrheic dermatitis. Sponsored by Arcutis Biotherapeutics, Inc., the trial focused on evaluating the effectiveness of ARQ-154 in treating this common skin condition. Completed in June 2020, this milestone represents a step forward in identifying potential treatments to alleviate the symptoms and improve the quality of life for individuals with seborrheic dermatitis.